Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Octanoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.81 |
| ▸ | PPARG | P37231 | 7/20 | 0.81 |
| ▸ | PPARD | Q03181 | 7/20 | 0.81 |
| ▸ | PPARA | Q07869 | 7/20 | 0.81 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.81 |
| ▸ | TSHR | P16473 | 4/20 | 0.81 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.81 |
| ▸ | FABP4 | P15090 | 3/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.81 |
| ▸ | TLR2 | O60603 | 2/20 | 0.81 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.81 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.81 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.81 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.81 |
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
| ▸ | ESR1 | P03372 | 1/20 | 0.81 |
| ▸ | PDE4A | P27815 | 1/20 | 0.81 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Stearic Acid SCHEMBL3846921 | 1.00 | GPR84 (0.81) | GPR84PPARGPPARDPPARAHDAC11 | |
| Dodecanoate SCHEMBL4163718 | 1.00 | GPR84 (0.81) | GPR84PPARGPPARDPPARAHDAC11 | |
| Myristic Acid SCHEMBL11877189 | 1.00 | GPR84 (0.81) | GPR84PPARGPPARDPPARAHDAC11 | |
| Hexacosanoic Acid SCHEMBL11757889 | 1.00 | GPR84 (0.81) | GPR84PPARGPPARDPPARAHDAC11 | |
| Palmitic Acid SCHEMBL11873354 | 1.00 | GPR84 (0.81) | GPR84PPARGPPARDPPARAHDAC11 | |
| Decanoic Acid SCHEMBL5159045 | 1.00 | GPR84 (0.81) | GPR84PPARGPPARDPPARAHDAC11 | |
| Heptanoate SCHEMBL2464651 | 1.00 | GPR84 (0.81) | GPR84PPARGPPARDPPARAHDAC11 | |
| Undecanoate SCHEMBL5303923 | 1.00 | GPR84 (0.81) | GPR84PPARGPPARDPPARAHDAC11 | |
| Dodecanoate SCHEMBL138673 | 0.98 | GPR84 (0.77) | GPR84PPARGPPARDPPARAHDAC11 | |
| Palmitic Acid SCHEMBL2459192 | 0.98 | GPR84 (0.77) | GPR84PPARGPPARDPPARAHDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110658338-A | Portable mastitis pathogen MRSA detection method in lactation period | 武汉大学 | 2020-01-07 | — | — | CN | claimed |
| US-20190262498-A1 | BIOADHESIVE PLATFORM TO PERFORM BIOACTIVE TREATMENT | FUNDACIÓ INSTITUT D'INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL (ES) | 2019-08-29 | — | — | US | claimed |
| EP-3490527-A1 | BIOADHESIVE PLATFORM TO PERFORM BIOACTIVE TREATMENT | Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (ES) | 2019-06-05 | — | — | EP | claimed |
| CN-109507435-A | GRP78 albumen double crush syndrome method detection kit and its detection method | 重庆医科大学 | 2019-03-22 | — | — | CN | claimed |
| CN-106831498-B | Furacilin metabolite SEM derivatizations haptens, artificial antigen preparation method and applications | 广州润坤生物科技有限公司 | 2018-10-30 | — | — | CN | claimed |
| CN-105503632-B | It is a kind of to be provided commonly for detecting crystal violet and haptens, the preparation method and applications of artificial antigen of malachite green | 广州润坤生物科技有限公司 | 2018-02-23 | — | — | CN | claimed |
| WO-2018019881-A1 | BIOADHESIVE PLATFORM TO PERFORM BIOACTIVE TREATMENT | FUNDACIÓ INSTITUT D'INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL (ES) | 2018-02-01 | — | — | WO | claimed |
| CN-105738618-B | A kind of Toxophasma gondii detecting kit | 浙江大学 | 2017-09-29 | — | — | CN | claimed |
| CN-107118159-A | Cistofuran metabolite AHD derivatizations haptens, the preparation method and applications of artificial antigen | 广州润坤生物科技有限公司 | 2017-09-01 | — | — | CN | claimed |
| CN-106866568-A | Furaxone metabolite AOZ derivatizations haptens, the preparation method and applications of artificial antigen | 广州润坤生物科技有限公司 | 2017-06-20 | — | — | CN | claimed |
| CN-106831498-A | Furacilin metabolite SEM derivatizations haptens, the preparation method and applications of artificial antigen | 广州润坤生物科技有限公司 | 2017-06-13 | — | — | CN | claimed |
| CN-106496323-A | A kind of cluster selectivity ochratoxin artificial antigen and its preparation method of broad spectrum activity polyclonal antibody | 华南农业大学 | 2017-03-15 | — | — | CN | claimed |
| US-20100291191-A1 | TUNABLE SUSTAINED RELEASE OF A SPARINGLY SOLUBLE HYDROPHOBIC THERAPEUTIC AGENT FROM A HYDROGEL MATRIX | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2010-11-18 | — | — | US | claimed |
| US-20100285113-A1 | ENHANCED STABILITY OF INVERSE THERMAL GELLING COMPOSITE HYDROGELS | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2010-11-11 | — | — | US | claimed |
| US-20230312700-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A TNF INHIBITOR | GLAS USA LLC | 2023-10-05 | — | — | US | disclosed |
| EP-4232146-A1 | METHODS OF TREATING AND PREDICTING NON-RESPONSE TO ANTI-TNF TREATMENT IN SUBJECTS WITH GASTROINTESTINAL TRACT DISEASES | Biora Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230041197-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNOMODULATOR | GLAS USA LLC | 2023-02-09 | — | — | US | disclosed |
| US-9205047-B2 | Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2015-12-08 | — | — | US | disclosed |
| US-20100291191-A1 | TUNABLE SUSTAINED RELEASE OF A SPARINGLY SOLUBLE HYDROPHOBIC THERAPEUTIC AGENT FROM A HYDROGEL MATRIX | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2010-11-18 | — | — | US | disclosed |
| US-20100285113-A1 | ENHANCED STABILITY OF INVERSE THERMAL GELLING COMPOSITE HYDROGELS | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041197-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNOMODULATOR | FABP2, IL2, TSLP | GPR84 2373/4885PPARG 563/4885PPARD 1148/4885 |
| US-20230312700-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A TNF INHIBITOR | TNF, TNFRSF1A, FABP2 | GPR84 2635/4885PPARG 2779/4885PPARD 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.